Order directly from
Alpha-1-antichymotrypsin (AACT) is a plasma protease inhibitor and member of the serine protease inhibitor class (SERPIN). AACT polymorphism is tissue specific and influences protease targeting. Variation in AACT sequence has been implicated in Alzheimer's disease, and activity deficiency has been associated with liver disease. Mutations have been identified in patients with Parkinson disease and chronic obstructive pulmonary disease.